Puretech Health PLC
ISIN: GB00BY2Z0H74 | Ticker: PRTC | LEI: 213800LVPDNO2Z9T9I39
Country: United Kingdom
Puretech Health PLC is a cutting-edge biotechnology company that is focused on developing and commercializing a wide range of innovative therapies in the healthcare industry. The company is based in the United Kingdom, and it has a growing presence in key markets around the world.
Puretech Health is dedicated to leveraging the latest scientific advances to create transformative medicines that improve human health and wellness. The company works closely with leading researchers, academic institutions, and industry partners to develop novel approaches to treating a wide range of medical conditions.
2005
Served areaWorldwide
Headcount111
Headquarters6 Tide St Ste 400, 02210-2412 Boston – United Kingdom
| Line item in (usd) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | N/A | 989,994,000.00 | 946,006,000.00 | 702,647,000.00 |
| Noncurrent Assets | N/A | N/A | 575,645,000.00 | 444,197,000.00 | 316,454,000.00 |
| Property Plant And Equipment | N/A | N/A | 22,777,000.00 | 26,771,000.00 | 22,957,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 899,000.00 | 987,000.00 | 831,000.00 |
| Investments In Associates | N/A | N/A | 0.00 | 0.00 | 9,147,000.00 |
| Noncurrent Receivables Due From Associates | N/A | N/A | N/A | 0.00 | 16,501,000.00 |
| Noncurrent Financial Assets At Fair Value Through Profit Or Loss | N/A | N/A | 530,161,000.00 | 397,179,000.00 | 251,892,000.00 |
| Noncurrent Finance Lease Receivables | N/A | N/A | 1,700,000.00 | 1,285,000.00 | 835,000.00 |
| Other Noncurrent Assets | N/A | N/A | 11,000.00 | 810,000.00 | 10,000.00 |
| Current Assets | N/A | N/A | 414,348,000.00 | 501,809,000.00 | 386,192,000.00 |
| Trade And Other Current Receivables | N/A | N/A | 2,558,000.00 | 3,174,000.00 | 11,867,000.00 |
| Current Receivables Due From Associates | N/A | N/A | 0.00 | 15,120,000.00 | 0.00 |
| Current Prepaid Expenses | N/A | N/A | 5,405,000.00 | 10,755,000.00 | 11,617,000.00 |
| Current Tax Assets Current | N/A | N/A | 0.00 | 4,514,000.00 | 10,040,000.00 |
| Cash and cash equivalents | 117,051,000.00 | 132,360,000.00 | 403,881,000.00 | 465,708,000.00 | 149,866,000.00 |
| Current Finance Lease Receivables | N/A | N/A | 381,000.00 | 415,000.00 | 450,000.00 |
| Equity And Liabilities | N/A | N/A | 989,994,000.00 | 946,006,000.00 | 702,647,000.00 |
| Equity | 167,971,000.00 | 650,398,000.00 | 653,539,000.00 | 584,147,000.00 | 547,589,000.00 |
| Issued Capital | N/A | N/A | 5,417,000.00 | 5,444,000.00 | 5,455,000.00 |
| Retained Earnings | N/A | N/A | 260,429,000.00 | 199,871,000.00 | 149,516,000.00 |
| Share Premium | N/A | N/A | 288,978,000.00 | 289,303,000.00 | 289,624,000.00 |
| Treasury Shares | N/A | N/A | N/A | 0.00 | 26,492,000.00 |
| Other Reserves | N/A | N/A | -24,050,000.00 | -40,077,000.00 | -14,478,000.00 |
| Merger Reserve | N/A | N/A | 138,506,000.00 | 138,506,000.00 | 138,506,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | 669,748,000.00 | 593,515,000.00 | 542,220,000.00 |
| Noncontrolling Interests | N/A | N/A | -16,209,000.00 | -9,368,000.00 | 5,369,000.00 |
| Liabilities | N/A | N/A | 336,455,000.00 | 361,859,000.00 | 155,057,000.00 |
| Noncurrent Liabilities | N/A | N/A | 155,531,000.00 | 135,725,000.00 | 58,172,000.00 |
| Deferred Tax Liabilities | N/A | N/A | 108,626,000.00 | 89,765,000.00 | 19,645,000.00 |
| Longterm Borrowings | N/A | N/A | 14,818,000.00 | 14,261,000.00 | 10,244,000.00 |
| Current Liabilities | N/A | N/A | 180,924,000.00 | 226,135,000.00 | 96,885,000.00 |
| Trade And Other Current Payables | N/A | N/A | 21,826,000.00 | 35,817,000.00 | 54,840,000.00 |
| Current Contract Liabilities | N/A | N/A | 1,472,000.00 | 65,000.00 | 2,185,000.00 |
| Current Derivative Financial Liabilities | N/A | N/A | 8,206,000.00 | 6,787,000.00 | 47,000.00 |
| Other Current Liabilities | N/A | N/A | 732,000.00 | 726,000.00 | N/A |
| Line item in (usd) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 9,807,000.00 | 11,768,000.00 | 17,388,000.00 | 15,618,000.00 |
| Revenue From Contracts With Customers | 8,688,000.00 | 8,341,000.00 | 9,979,000.00 | 2,090,000.00 |
| Other Income | 672,167,000.00 | 178,732,000.00 | 159,983,000.00 | N/A |
| Other Gains Losses | 39,000.00 | 1,035,000.00 | 1,592,000.00 | 8,131,000.00 |
| Profit Loss From Operating Activities | -135,399,000.00 | -119,531,000.00 | -150,282,000.00 | -197,807,000.00 |
| Finance Income | 4,362,000.00 | 1,183,000.00 | 214,000.00 | 5,799,000.00 |
| Finance Costs | 2,576,000.00 | 2,946,000.00 | 4,771,000.00 | 3,939,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | 30,791,000.00 | -34,117,000.00 | -73,703,000.00 | -27,749,000.00 |
| Profit Loss Before Tax | 478,474,000.00 | 18,969,000.00 | -58,953,000.00 | -92,783,000.00 |
| Income Tax Expense Continuing Operations | 112,409,000.00 | 14,401,000.00 | 3,756,000.00 | -55,719,000.00 |
| Profit (loss) | 366,065,000.00 | 4,568,000.00 | -62,709,000.00 | -37,065,000.00 |
| Profit Loss Attributable To Owners Of Parent | 421,144,000.00 | 5,985,000.00 | -60,558,000.00 | -50,354,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | -55,079,000.00 | -1,417,000.00 | -2,151,000.00 | 13,290,000.00 |
| Line item in (usd) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | N/A | 366,065,000.00 | 4,568,000.00 | -62,709,000.00 | -37,065,000.00 |
| Adjustments For Income Tax Expense | N/A | 112,077,000.00 | 14,402,000.00 | 3,756,000.00 | -55,719,000.00 |
| Adjustments For Finance Costs | N/A | 46,229,000.00 | 6,114,000.00 | -5,050,000.00 | N/A |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | 11,166,000.00 | 605,000.00 | 8,338,000.00 | 22,033,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | 3,002,000.00 | -7,000.00 | 0.00 | N/A |
| Adjustments For Depreciation And Amortisation Expense | N/A | 6,665,000.00 | 6,645,000.00 | 7,287,000.00 | 8,893,000.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | N/A | N/A | 0.00 | 0.00 | 8,390,000.00 |
| Adjustments For Sharebased Payments | N/A | 14,468,000.00 | 10,718,000.00 | 13,950,000.00 | 14,698,000.00 |
| Adjustments For Fair Value Gains Losses | N/A | 37,863,000.00 | -232,674,000.00 | -179,316,000.00 | 32,060,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | 0.00 | 54,976,000.00 | 20,925,000.00 | 29,303,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 2,495,000.00 | 2,651,000.00 | 3,382,000.00 | 3,366,000.00 |
| Interest Received Classified As Operating Activities | N/A | 3,648,000.00 | 1,155,000.00 | 214,000.00 | 3,460,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 0.00 | 20,737,000.00 | 27,766,000.00 | 20,696,000.00 |
| Other Inflows Outflows Of Cash Classified As Operating Activities | N/A | 0.00 | -7,000.00 | -103,000.00 | 359,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -98,156,000.00 | -131,827,000.00 | -158,274,000.00 | -178,792,000.00 |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | -16,036,000.00 | 0.00 | 0.00 | N/A |
| Other Cash Receipts From Sales Of Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 9,294,000.00 | 350,586,000.00 | 218,125,000.00 | 118,710,000.00 |
| Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 1,556,000.00 | 1,150,000.00 | 500,000.00 | 5,000,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 0.00 | 30,000.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 12,138,000.00 | 5,170,000.00 | 5,571,000.00 | 2,176,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 400,000.00 | 254,000.00 | 90,000.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | 63,659,000.00 | 364,478,000.00 | 197,375,000.00 | -107,223,000.00 |
| Payments From Changes In Ownership Interests In Subsidiaries | N/A | 0.00 | 0.00 | 806,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,678,000.00 | 2,908,000.00 | 3,375,000.00 | 4,025,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | 0.00 | 0.00 | -5,000.00 | -41,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 49,910,000.00 | 38,869,000.00 | 22,727,000.00 | -29,827,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | N/A | 271,520,000.00 | 61,827,000.00 | -315,842,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -104,000.00 | 0.00 | 0.00 | N/A |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 15,309,000.00 | 271,520,000.00 | 61,827,000.00 | N/A |
| Cash and cash equivalents | 117,051,000.00 | 132,360,000.00 | 403,881,000.00 | 465,708,000.00 | 149,866,000.00 |
Please note that some sums might not add up.
GB00BY2Z0H74
LEI213800LVPDNO2Z9T9I39
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryFTSE 250
Main Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.